it would be awesome if someone financed us, and wanted to spend the money exploring if their tech works!!!
They should have sold off 25% of Senesco 5 years ago, to be fully fund trials, would have saved us from the billion or so in dilution.. say la vie.
Harlan is a used car sales person.. he will change his story to fit whatever happens. If stuff goes wrong, he will state that he is opposing it. DO NOT LISTEN TO HIM... lesson most of us learned the hard way
they are idiot - its not novel, and their targets are trying to improve current drugs...we are looking at marginally improving, if anything.
I think what he should be saying is, we are broke...but we are going to keep focusing on our preclinical until such time we are out of money and have to do another really dilutive financings...at that time, we still will not have enough money to do a second cohort so we will have to figure out what we are going to do..i.e. sell off eif5a tech or sell of fabrus tech. We do not have enough resources to pursue both..oooppss Harlan misjudged it and made a bad business call again
Im not to sure of what their business strategy is. They never had enough money to pursue all their drugs.. and it took over 6 months to close such a small transaction. He agreed to add money only at a 60% discount to the then $5 market price, plus three traunches of warrants. That deal alone caused major selling. The delay in closing the merger, lack of clear strategy given the limited resources...the wishy washy info on direction of eift5a...their very early stage pipeline of fabrus, plus their targets (which are questionable), the lack luster results of eif5a (although there is some promise there)... You kind of start to understand why its selling of.
Without a doubt eif5a will change how cancer is treated and looked at...hopefully they can figure out how to manipulate it effectively. Fabrus tech will be worth something too...as they should prove to be less toxic then current treatments (for the ones that show promise)...but now we are faced with multiple tranches of financing, no real clear path or timeline, (my belief) we are no where near a partnership unless it is with another jr company that has some cash... Im actually thinking they will try and spin out eif5a..I can almost see Harlan brothers company picking it up on the cheap...putting cash in the till for fabrus tech development (pure speculation, but I would not put that fraud past Harlan, given he is now the CEO)
many many very successful and rich individuals take losses too. And, he was under pressure to get some liquidity for Fabrus...his hands were a bit tied also. So....
I dont think there will be. You don't let go of the industry expert on eif5a, when your partnering up...if the announced they retained JT..i would be more optimistic..
Not zero - but on a steady decline as they do more and more dilutive financings.
Whose doing the buying: guessing people that know frost, believe he is onto something and looking for panic seller. Frost has money - but I think they are overly excited with Fabrus tech...which might be worth something..but nowhere near what eif5a tech would be worth if they figured it out.
i have a feeling someone spoke with management and figured out that the results are what they are, there is no surprises at the AHS meeting.
Without money, it makes it next to impossible to move if forwards, especially if they are still spending money pursing other avenues....I almost sold too (but I am emotionally attached to my last little bit..as it dwindle closer and closer into nothing)
That would be awesome if they found a partner...especially one that will give them milestones....still think it will be a few years to materialize.
The more I contemplate cohort 4's results, Im thinking we are several years away from anything significant. Even if we get a JV combination study, it wouldn't start till q2 (likely) next year, and would likely last 1 - 1.5 years (unless it was a small redo of phase 1/2). All of Fabrus leads are still a year away from filling an IND..could be a year after that before trials.
Not much on the horizon...so I too am thinking several rounds of dilutive financing to keep them going. (basically more of the same over the last 10 years)
just a guess: 2 from cohort 4 with DLT and there was a guy that dropped out late in dosing because he was too sick...think it was cohort 2.
Or, it could be 3 from cohort 4, as there is a period of time they need to follow them up. They might not have the final data for the 3 as the period was not ended yet. (maybe.)
Again, just a guess
I would like to breakeven.
Still don't know if a combination is in play...sure they would like one, but no signs of one and the data isn't staggering.
Agreed - completely think combination study is in order. not to sure why some of the results are missing....
Hopefully they figure out how to get more of the siRNA into the cell nucleus. hopefully.
Treatment-emergent adverse events (TEAE) were reported for all pts. The most frequently reported System Organ Classes were General Disorders and Administration Site Conditions (72%) and Gastrointestinal Disorders (56%), with somewhat higher reporting frequency in dose cohorts 3 and 4. The most commonly reported AEs were fatigue (50%), nausea (33%), infusion-related reaction (33%), chills (28%), thrombocytopenia (22%) and pyrexia (17%). Thrombocytopenia, nausea, fatigue, infusion reaction appeared to show some degree of dose relationship. Grade ≥3 TEAEs occurred in 50% of pts with no obvious dose relationship. The only grade ≥3 TEAE reported in 1 pt was thrombocytopenia (17%). There have been no treatment-related deaths. There was 1 DLT at dose level 4 (0.375 mg/kg). Pt 51-001 did not receive premedication prior to the third infusion of SNS01-T and consequently experienced a grade 4 infusion reaction, from which all symptoms resolved within 24 hours. Study treatment was discontinued and the protocol was amended to require the following premedication at each SNS01-T infusion: a corticosteroid, antihistamine and acetaminophen are obligatory, plus an opioid as clinically indicated.
Preliminary efficacy was explored. To date, 2 pts have shown stable disease of myeloma at week 3 with some decrease in serum and urine disease markers and one pt with DLBCL had a 15% decrease in small lymph node disease with approximately a 5 month duration. These patients were in cohorts 3 and 4.
SNS01-T administration was feasible in all 4 dose cohorts with prophylaxis for infusion reactions. Early signs of potential efficacy are encouraging. Expansion of efficacy testing to more patients and combination studies are planned.
Well the results are not explosive...but at least there are some future plans of combination study (likely delayed due to money). Explains the sell off
I hope they rethink their new strategy focusing on licensing all their technology...markets down 10% on signing up a partner to use the tech as delivery.
You got a potential 900lb gorilla game changer with the eif5a tech, and they are focusing on the scraps... who does that? Or maybe, doing small licensing deals for all the tech is what they should be focused on...
I do appreciate how they announce this and the only thing that matters on this board is the AHS announcement...which is the only thing that matter. It amazes me they don't seem to see that.
That would be great! They have been shopping it around since they started clinical trials...
From what I read, that is their last hope...have someone else pick it up for a combination study, or outright by it. If that was their motivation, why put in the 10q that one of their options to stop development... Think there is enough data to attract a partner?
Harlan has noted he doesn't think sns01-t will make it to market in its current form (this was just after cohort 3).
Without the partnership, we are faced with the hard reality that they do not have enough money to do a phase 2, or even a phase one for the entire pipeline on their website (and Im sure there are others). And, their lack of direction/ conviction, will keep pushing this stock lower, forcing another highly dilutive financing.
Dec will be interesting, to say the least. Hope long have you been a shareholder? What brought you to the story?
We have gone from a company that could revolutionize how cancer gets treated. Now its a monoclonal antibody, that is hoping to be less toxic then current drugs targeting various cellular sites. Harlan is an #$%$ hat!... The underhandedly switch the focus of the company without shareholder approval. Days like this I wish I had money to sue.